EP. 1: Targeted Pulse Quiz: September 1
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
EP. 2: The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast Track Designation and Sonrotoclax Plus Zanubrutinib Showing Promise, and More
The FDA fast-tracked BGB-16673 for advanced CLL/SLL, Ticiana Leal, MD, compares lurbinectedin and topotecan for extensive-stage SCLC, and sonrotoclax and zanubrutinib show improved results in early CLL/SLL trials.
EP. 3: Targeted Pulse Quiz: September 8
EP. 4: The Targeted Pulse: IL-21 Promises to Revolutionize Treatment for Glioblastoma, Pembrolizumab Trials Halted in Lung and Skin Cancer, and More
IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.
EP. 5: The Targeted Pulse: IBI363’s Fast Track Status Set to Transform Melanoma, Subcutaneous Bortezomib Receives Approval for MM and MCL Management, and More
The FDA granted IBI363 fast track status for melanoma and approved a ready-to-use subcutaneous bortezomib for MM and MCL. We also cover new data highlighting the efficacy of lenvatinib/pembrolizumab in nccRCC, cost-effectiveness of TKIs for CML, and innovative immunotherapies for T-cell malignancies.
EP. 6: Targeted Pulse Quiz: September 22
EP. 7: The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS G12C-NSCLC, Adding Nivolumab to Tivozanib Yields No benefit in RCC, and More
Adagrasib bests docetaxel in pretreated KRAS G12C-NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.
EP. 8: The Targeted Pulse: NKT2152 Sparks Excitement in RCC, Amivantamab/Chemotherapy Combo Receives Approval for EGFR-Mutant NSCLC, and More
NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose of the trastuzumab biosimilar and offer a focused recap of intriguing data presented at this year’s ESMO Congress.
EP. 9: Targeted Pulse Quiz: September 29
